DFH Pharma, Hetero Group Partner on Developing Second-Generation HIV Maturation Inhibitor Drugs

The pharmaceutical firms are looking to develop treatments that block replication of the virus.

DFH Pharma, Inc., a privately held pharmaceutical company focused on the development of HIV therapeutics, announced that it has entered into a Research and Product Development Agreement with Hetero Group ("HETERO"), a privately held research-based global pharmaceutical group with headquarters in Hyderabad, Andhra Pradesh, India, to develop the next generation of HIV maturation inhibitor drugs.

No votes yet

Immunotech Laboratories Attains Funding Partner on HIV Treatment Trials

The pharmaceutical development firm has received backing to conduct U.S. clinical trials for various HIV treatments.

Immunotech Laboratories, Inc. today announced the company has been in negotiations with an International Bio-Tech Partner in the HIV cure technology sector for joint advanced Research & Development and the partner has agreed to provide the necessary funding for the USA Clinical Trials phases to ultimately achieve FDA approval for the medicines.

Your rating: None Average: 5 (1 vote)

Anti-diarrheal Treatment for HIV/AIDS Patients Attains Approval

Fulyzaq is indicated for relief of symptoms in patients taking antiretroviral therapy to treat HIV infection.

The U.S. Food and Drug Administration today approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection.

No votes yet

HIV Treatment Receives Stronger Label Warnings After Call From Advocates

Advocacy groups moved the FDA to call for packaging of Truvada to bear a “black box warning” after its earlier approval as an HIV prevention pill.

AIDS Healthcare Foundation (AHF), the nation’s largest HIV/AIDS nonprofit medical provider, welcomed the news today the boxed warning label (also called the ‘black box warning’) on Gilead Sciences’ blockbuster AIDS treatment Truvada for use as a form of an HIV prevention pill appears much stronger than proposed versions of the label earlier this year.

Your rating: None Average: 3 (1 vote)

FDA Okays New HIV Combo Pill

The agency has approved Stribild, a new once-a-day combination pill for treating HIV-1 infection in newly diagnosed patients.

The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

No votes yet

Hope for HIV/Aids Fight

[AllAfrica]-Two new studies in Uganda and Kenya have shown that the use of anti-retroviral drugs can effectively reduce HIV/Aids infections among heterosexuals, according to results released yesterday.

The study was led by the University of Washington's International Clinical Research Centre and involved 4,758 HIV sero-discordant couples from nine sites in the two countries. Sero-discordance is where one partner has HIV and the other does not.

Less infection

Syndicate content